Earnings Call Summary | BiomX(PHGE.US) Q1 2024 Earnings Conference
Earnings Call Summary | BiomX(PHGE.US) Q1 2024 Earnings Conference
The following is a summary of the BiomX (PHGE) Q1 2024 Earnings Call Transcript:
以下是BiomX(PHGE)2024年第一季度業績電話會議記錄的摘要:
Financial Performance:
財務業績:
BiomX reported a cash balance and short-term deposits of $44.1 million as of March 31, 2024, a significant increase from $30.3 million in the same period of 2023.
Research and development expenses for Q1 2024 are slightly lower, totalling $4.1 million, as compared to $4.6 million for the same period in 2023.
The company recorded a notable increase in general and administrative expenses for Q1 2024 amounting to $2.7 million, up from $1.6 million for the same period in 2023.
The net loss for Q1 2024 was significantly more than last year, at $17.3 million compared to $6.4 million in Q1 2023.
BiomX報告稱,截至2024年3月31日,現金餘額和短期存款爲4,410萬美元,較2023年同期的3,030萬美元大幅增加。
2024年第一季度的研發費用略有下降,總額爲410萬美元,而2023年同期爲460萬美元。
該公司2024年第一季度的一般和管理費用顯著增加,總額爲270萬美元,高於2023年同期的160萬美元。
2024年第一季度的淨虧損明顯超過去年,爲1,730萬美元,而2023年第一季度爲640萬美元。
Business Progress:
業務進展:
After the merger with Adaptive Phage Therapeutics in March 2024, BiomX is progressing with a second Phase II product candidate, BX211, aimed at treating diabetic foot osteomyelitis.
Their leading clinical stage candidate, BX004, has shown encouraging results for treating chronic infections in cystic fibrosis patients.
Thanks to current funding, BiomX expects to reach multiple clinical milestones through 2025, including the expected data read-outs for lead candidates, BX211 and BX004.
The company also plans to submit a Phase 2b study protocol for BX004 to all relevant regulatory authorities and commence the study by the end of 2024.
BiomX's top line results of the Phase 2b study are expected to be released in the third quarter of 2025.
在 2024 年 3 月與 Adaptive Phage Therapeutics 合併後,BiomX 正在開發第二款二期候選產品 BX211,該產品旨在治療糖尿病足骨髓炎。
他們的主要臨床階段候選藥物 BX004 在治療囊性纖維化患者的慢性感染方面顯示出令人鼓舞的結果。
得益於目前的資金,BiomX預計到2025年將達到多個臨床里程碑,包括主要候選人 BX211 和 BX004 的預期數據讀取。
該公司還計劃向所有相關監管機構提交 BX004 的 2b 期研究方案,並在 2024 年底之前開始研究。
BiomX的2b期研究的主要結果預計將在2025年第三季度發佈。
More details: BiomX IR
更多詳情: BiomX 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。